Imatinib

5 mg



Orders 877-616-CELL (2355)

orders@cellsignal.com

Support 877-678-TECH (8324)

info@cellsignal.com

Web www.cellsignal.com

rev. 06/04/19

For Research Use Only. Not For Use In Diagnostic Procedures.

Background: Imatinib is a tyrosine kinase (TK) inhibitor that is a relatively specific ATP-binding site antagonist of Bcr-Abl, PDGF receptor, and c-Kit TKs (1-3). Results are encouraging in chronic myeloid leukemia (CML) clinical trials and imatinib has become a paradigm for targeted cancer therapeutics (4-6). Signal transduction through phosphotyrosine pathways has been studied extensively, and tyrosine phosphorylation has been linked to multiple cell growth and differentiation pathways (7-9). Because the observed leukemic state of CML is dependent on the intact Bcr-Abl tyrosine kinase activity, extensive work has been done to identify substrates of Bcr-Abl and thus possible mechanisms leading to a myeloid expansion. Many groups have characterized prominent tyrosine-phosphorylated protein substrates in both CML blasts and Bcr-Abl-expressing cell lines, including SHIP, c-Cbl, Dok, Shc, and CrkL (10-15). In addition, key signal transduction pathways involving PI3 kinase, Ras, Myc, and Stat5 are also activated in a Bcr-Abl kinase-dependent manner (16).


Molecular Formula: $C_{20}H_{21}N_7O + CH_4SO_2$

Molecular Weight: 589.71 g/mol

Solubility: Soluble in DMSO at 100 mg/ml; poorly soluble in ethanol. Soluble in water at 200 mg/ml.

Purity: >99%.

Directions for Use: Imatinib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 847.9 μ l DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-10 μ M for 1-2 hours.



Western blot analysis of extracts from K562 cells, untreated (-) or treated with Imatinib (10uM for 1 hr), using Phospho-Stat5 (Tyr694) (C11C5) Rabbit mAb #9359 (upper), Stat5 (D3N2B) Rabbit mAb #25656 (middle), and α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower).

Storage: Store lyophilized or in solution at -20°C, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Background References:

- (1) Buchdunger, E. et al. (1996) Cancer Res 56, 100-4.
- (2) Heinrich, M.C. et al. (2000) Blood 96, 925-32.
- (3) Druker, B.J. et al. (1996) Nat Med 2, 561-6.
- (4) Mauro, M.J. and Druker, B.J. (2001) Curr Oncol Rep 3, 223-7.
- (5) Druker, B.J. et al. (2001) N Engl J Med 344, 1031-7.
- (6) Druker, B.J. et al. (2001) N Engl J Med 344, 1038-42.
- (7) Blume-Jensen, P. and Hunter, T. (2001) Nature 411, 355-65.
- (8) Ullrich, A. and Schlessinger, J. (1990) Cell 61, 203-12.
- (9) Cantley, L.C. et al. (1991) Cell 64, 281-302.
- (10) ten Hoeve, J. et al. (1994) Blood 84, 1731-6.
- (11) Matsuguchi, T. et al. (1994) J Biol Chem 269, 5016-21.
- (12) Carpino, N. et al. (1997) Cell 88, 197-204.
- (13) Sattler, M. et al. (1997) Oncogene 15, 2379-84.
- (14) Di Cristofano, A. et al. (1998) J Biol Chem 273, 4827-30.
- (15) Wisniewski, D. et al. (1999) Blood 93, 2707-20.
- (16) Kabarowski, J.H. and Witte, O.N. (2000) *Stem Cells* 18, 399-408.